Doctors Revision

Antiretroviral Therapy (ART): Drug Classes, Regimens and Monitoring

Text size
On this page

Overview

Drug classes and the HIV life cycle

Each ART class blocks a different step of HIV replication (figure 1). Combination ART (cART) — at least three drugs from at least two classes — suppresses viral replication to undetectable levels, allows immune recovery, and makes onward transmission effectively zero (U=U: undetectable = untransmittable).

Figure 1: Simplified HIV replication cycle with the five steps, the drug class acting at each step, and Uganda first-line regimen TDF plus 3TC plus dolutegravir
Figure 1: The five steps of HIV replication and the drug classes that block them.

Scroll the table sideways on a smaller screen.

The five ART classes at a glance
ClassTarget / mechanismAgentsResistance barrierRole
Nucleoside reverse transcriptase inhibitors (NRTIs)Incorporated into viral DNA by reverse transcriptase, then terminate the chain (compete with natural nucleotides)Tenofovir (TDF/TAF), lamivudine (3TC), emtricitabine (FTC), zidovudine (AZT), abacavir (ABC)Low–moderateTwo NRTIs form the backbone of every regimen
Non-nucleoside RT inhibitors (NNRTIs)Allosteric binding to reverse transcriptase — non-competitive inhibitionEfavirenz (EFV), nevirapine (NVP), rilpivirine (RPV), doravirineLow (single mutation, e.g. K103N, confers cross-resistance)Formerly first-line third drug; falling out of favour with DTG scale-up
Integrase strand transfer inhibitors (INSTIs)Block integrase — viral DNA cannot insert into the host genomeDolutegravir (DTG), bictegravir, raltegravir, elvitegravirHigh (DTG)Preferred third drug — Uganda and WHO first line
Protease inhibitors (PIs)Block viral protease — immature, non-infectious virions resultLopinavir/r (LPV/r), atazanavir/r (ATV/r), darunavir/r (DRV/r)High (need multiple mutations; ritonavir boosting)Second-line anchor; special situations (young children)
Entry / fusion inhibitorsBlock CCR5 co-receptor (maraviroc) or gp41 fusion (enfuvirtide)Maraviroc, enfuvirtide—Third-line/specialist only

NRTIs in detail

Scroll the table sideways on a smaller screen.

The NRTIs: dose, adverse effects, contraindications, counselling
DrugAdult dosePaediatric doseMain usesAdverse effectsContraindications / interactionsCounselling
Tenofovir disoproxil fumarate (TDF)300 mg once daily (fixed with 3TC + DTG as TLD)As FDC by weight band (child dosing per national chart)First-line backbone NRTI; also hepatitis B monotherapyRenal tubular toxicity (check creatinine/eGFR), reduced bone density, nausea; rare Fanconi syndrome; lactic acidosis/hepatic steatosis (class effect, rare)Avoid if eGFR <60 (use ABC/AZT per guidelines); nephrotoxic co-drugs (aminoglycosides, amphotericin, tenofovir + boosted PIs ↑ levels)Take with or without food; report muscle weakness, bone pain, passing less urine; do not stop if also treating HBV (flare risk)
Lamivudine (3TC)300 mg once dailyWeight-bandBackbone NRTI in virtually every regimen; also anti-HBVVery well tolerated; headache, nausea; pancreatitis (rare, children); lactic acidosis (rare)None significantNever stop alone if HBV co-infected (flare)
Zidovudine (AZT)300 mg 12-hourlyWeight-bandAlternative backbone (renal impairment); second-line anchor partnerMacrocytic anaemia/neutropenia (monitor FBC at 4–6 wks), nausea, headache, myopathy, lipoatrophy, lactic acidosis, neonatal use safeAvoid if baseline Hb low; stavudine (d4T) withdrawn — same class toxicity (avoid re-challenge)Report pallor, breathlessness, unusual tiredness (anaemia)
Abacavir (ABC)600 mg once dailyWeight-bandBackbone alternative (e.g. TDF contraindicated, adolescents <35 kg)Hypersensitivity reaction (HSR) — fever, rash, GI, respiratory; can be fatal on re-challenge; lactic acidosis (rare)Do NOT re-challenge after HSR (always document!); test HLA-B*57:01 where availableReport fever/rash immediately; carry the warning card

NNRTIs in detail

Scroll the table sideways on a smaller screen.

The NNRTIs: dose, adverse effects, contraindications, counselling
DrugAdult dosePaediatric doseMain usesAdverse effectsContraindications / interactionsCounselling
Efavirenz (EFV)600 mg once daily at nightWeight-band (200–400 mg by weight); <3 yr avoidFormer first-line third drug; still widely used; TB co-treatment compatible (600 mg maintained)CNS effects — vivid dreams, dizziness, poor concentration (weeks 1–2, usually settle); rash; raised lipids; possible neural-tube-defect signal in early pregnancy (low absolute risk)Psychiatric illness (depression/suicidality — caution); CYP3A4 inducer (↑ metabolism of many drugs, ↓ contraceptive efficacy, ↓ voriconazole, ↓ some anticoagulants)Take at bedtime; avoid driving until settled; do not stop for vivid dreams alone; use reliable contraception
Nevirapine (NVP)200 mg once daily ×14 d, then 200 mg 12-hourlyWeight-bandAlternative first-line; PMTCT regimens; childrenRash → SJS/TEN (lead-in dosing halves risk; stop at rash), hepatotoxicity (monitor LFTs; higher in women with CD4 >250/men >400)Hepatic impairment; never start if CD4 above thresholds in adults; enzyme inducerReport any rash at once; take lead-in dose exactly
Rilpivirine (RPV)25 mg once daily with food>12 y onlyAlternative (not with baseline viral load >100,000; not with TB on rifampicin)Rash, depression, insomniaGastric pH — avoid PPIs, separate antacids; food requirement (with a meal)Always take with a meal

Integrase inhibitors (INSTIs)

Scroll the table sideways on a smaller screen.

Dolutegravir (DTG): the preferred INSTI
ItemDetails
Dose50 mg once daily (TLD fixed-dose combination); 50 mg twice daily when co-treated with rifampicin (and for some INSTI resistance); separate from polyvalent cations (antacids, calcium, iron — take 2 h apart)
MechanismBinds integrase active site → viral DNA cannot integrate into host genome; high genetic barrier to resistance (requires multiple mutations)
Adverse effectsGenerally very well tolerated; insomnia, headache; weight gain (notable metabolic signal); rare hypersensitivity with liver injury
InteractionsRifampicin → double the dose; polyvalent cations chelate (separate dosing); metformin levels ↑ (monitor)
Special pointsSafe in pregnancy/breastfeeding (preferred by Uganda 2020+ guidance); rapid viral suppression; long half-life forgiving of occasional missed doses

Protease inhibitors (PIs)

Scroll the table sideways on a smaller screen.

Protease inhibitors: dose, adverse effects, interactions
DrugDoseUsesAdverse effectsInteractions / cautions
Lopinavir/ritonavir (LPV/r)400/100 mg 12-hourly (tablets); paediatric syrup weight-bandChildren <3 y (with ABC+3TC); second lineGI upset (very common), lipid elevation, insulin resistance/diabetes, fat redistribution, QT prolongationRitonavir = potent CYP3A4 inhibitor → huge interaction list (statins contraindicated except pravastatin; ↑ rifabutin; many others); avoid with rifampicin
Atazanavir/ritonavir (ATV/r)300/100 mg once dailySecond line (adults)Indirect hyperbilirubinaemia (harmless jaundice), nephrolithiasis, PR prolongation, rashAs LPV/r; requires gastric acid (separate antacids/H2 blockers); avoid rifampicin
Darunavir/ritonavir (DRV/r)800/100 mg once dailyThird line / salvageRash (SJS rare), hepatotoxicity, lipidsResistance testing needed; specialist use

PIs are always "boosted" with a small dose of ritonavir (or cobicistat) that inhibits CYP3A4, raising and prolonging the PI level — this is a pharmacokinetic enhancer, not an antiviral.

Uganda regimens and special populations

Scroll the table sideways on a smaller screen.

ART regimens per Uganda Consolidated HIV Guidelines (test-and-treat: ART for all PLHIV regardless of CD4)
PopulationFirst lineAlternatives / second line
Adults & adolescents ≥10 yTDF + 3TC + DTG (TLD) once dailyTDF+3TC+EFV; ABC+3TC+DTG if TDF contraindicated (eGFR <60, <35 kg). Second line: AZT+3TC + ATV/r (or LPV/r), guided by viral load
Children 3–<10 yABC + 3TC + DTG (per national optimisation)ABC+3TC+EFV; second line PI-based
Children <3 yABC + 3TC + LPV/r (high resistance barrier; NVP failed too often)ABC+3TC+RAL in some settings
Pregnancy / breastfeedingTLD (DTG preferred; EFV alternative)As adults; do not delay ART
TB co-treatmentTLD with DTG 50 mg twice daily during rifampicin (EFV needs no adjustment)Avoid PI + rifampicin combination
  • Baseline before ART: HIV confirmation, CD4 (severity/OI risk), viral load, HBsAg (HBV changes regimen), creatinine/eGFR (TDF), FBC (if AZT), TB screening (symptom screen ± Xpert), pregnancy test, STI screen.
  • Monitoring: viral load at 6 and 12 months then annually (target <1000 copies/mL = suppressed); adherence counselling at every visit; clinical staging.

PEP, PrEP and PMTCT

  • Post-exposure prophylaxis (PEP): after occupational or sexual exposure, start TDF+3TC+DTG (or TLD) within 72 hours (ideally <2 h), for 28 days; baseline HIV test, follow-up testing at 6 weeks, 3 months (and 6 months per guidelines). Do not delay the first dose for testing.
  • Pre-exposure prophylaxis (PrEP): TDF/FTC (or TDF/3TC) daily for HIV-negative people at substantial risk — serodiscordant couples, key populations; requires regular HIV testing (drug resistance if given during undiagnosed acute HIV).
  • PMTCT: ART for all HIV-positive pregnant/breastfeeding women (lifelong), infant prophylaxis (e.g., NVP or AZT syrup per national protocol), safe infant feeding counselling, and early infant diagnosis at 6 weeks (DNA PCR).
  • U=U: sustained viral suppression means no sexual transmission — a powerful adherence motivator.

Adverse effects, interactions and adherence

Scroll the table sideways on a smaller screen.

High-yield ART interactions
Partner drugARV affectedEffect / action
Rifampicin (TB)DTG↓ DTG levels → DTG 50 mg twice daily
RifampicinPIs (LPV/r, ATV/r, DRV/r), RPV, most NNRTIsMarked ↓ levels → avoid PI combinations; EFV 600 mg maintained; specialist input
Ritonavir/cobicistat (boosters)Statins (simvastatin/lovastatin), rifabutin, some anticoagulants, sedatives↑ partner levels → simvastatin contraindicated; reduce rifabutin dose
Polyvalent cations (antacids, Ca, Fe, Mg)DTG (and RPV)Chelation → separate by 2 h (DTG before or after)
Carbamazepine, phenytoin, phenobarbitalDTG, PIs, many ARVsEnzyme induction → avoid or adjust with specialist advice
Oral contraceptivesEFV, rifampicin-containing TB therapy↓ contraceptive levels → add condoms or switch method

Clinical scenarios

Scenario 1 — Starting ART at the HIV clinic

A 29-year-old woman, newly diagnosed (CD4 320, viral load 45,000, HBsAg negative, eGFR normal, not pregnant), is started on TLD once daily the same day (test and treat). You counsel: take the same time daily; if she starts TB treatment she will need the twice-daily dolutegravir adjustment; separate from iron tablets and antacids; expect viral suppression by 6 months; and that with sustained suppression she cannot transmit HIV sexually. Follow-up: viral load at 6 months — detectable VL with good adherence prompts enhanced support first, then resistance testing if persistent.

Scenario 2 — Needle-stick injury at the ward

A house officer sustains a deep needle-stick from an HIV-positive patient (viral load unknown) during a procedure. You wash the wound, don't squeeze it, and start PEP (TLD) within 2 hours — 28 days, after baseline HIV/HBV/HCV and pregnancy tests (she is not pregnant). You counsel on side effects, schedule follow-up tests, and remind her the regimen must be completed even if the source's tests return negative-ish patterns. First dose never waits for paperwork.

Scenario 3 — Rash on nevirapine

A 41-year-old man, 10 days into TDF+3TC+NVP (lead-in completed), develops a widespread maculopapular rash with fever. You stop all ARVs immediately (NVP SJS/TEN risk) — and counsel that he must never take NVP again. You switch his regimen per guidelines once the rash resolves (e.g., to TLD if no contraindication) with close early review. Document the reaction in his booklet and the clinic register.

Key points

References

  • Uganda Consolidated Guidelines for Prevention and Treatment of HIV and AIDS (MoH, 2020 revision and updates) (Library reference.)
  • WHO Consolidated Guidelines on the Use of Antiretroviral Drugs (Library reference.)
  • WHO HIV/AIDS fact sheets: ART coverage and U=U statements (Library reference.)
  • Katzung's Basic & Clinical Pharmacology — antiviral agents chapter (Library reference.)
  • Goodman & Gilman's The Pharmacological Basis of Therapeutics (Library reference.)

Further reading

For deeper study, compare this lesson with current guidance and standard references from recognised medical and pharmaceutical organisations.

For education only. ART must be prescribed per the current Uganda Consolidated HIV Guidelines and national ART programme — verify regimens, interactions and monitoring schedules in practice.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top